Duality Advisers’s Harmony Biosciences HRMY Stock Holding History

Duality Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,864	Closed	-$331K	–	243
2024 Q1	$331K	Buy	9,864 +1,810	+22%	+$58.1K	0.03%	506
2023 Q4	$260K	Buy	+8,054	New	+$225K	0.03%	519

Other funds holding HRMY

Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Duality Advisers's HRMY Position: Q2 2024 in Review

Duality Advisers sold out of Harmony Biosciences (HRMY) in Q2 2024, closing a stake of 9,864 shares — an estimated $331K sold.

Duality Advisers first reported a position in HRMY in Q4 2023 and held it in 2 quarters. The position peaked at $331K in Q1 2024. 219 funds tracked by Wall St. Rank hold HRMY as of Q2 2024.

Duality Advisers reported no remaining Harmony Biosciences position as of Q2 2024 after selling out during the quarter.
Duality Advisers sold 9,864 Harmony Biosciences shares in Q2 2024, an estimated $331K.
Duality Advisers first reported a position in Harmony Biosciences in Q4 2023 and held it in 2 quarters.
Duality Advisers's Harmony Biosciences position peaked at $331K in Q1 2024.
219 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.